糖心原创

School of Life Sciences
 

Madeleine King

Assistant Professor, Faculty of Medicine & Health Sciences

Contact

Biography

I graduated from the University of Bath in 2002 with a MSci in Pharmacology, which included an industrial placement in the Behavioural Neuroscience department of the Merck Sharp & Dohme Neuroscience Research Centre. I moved to Nottingham to complete a Roche-funded PhD on the role of 5-HT6 receptors in memory and attention, followed by post-doctoral research on a multicentre EU FP6-funded project, developing novel models for glutamatergic CNS disorders using short hairpin RNA approaches. I was appointed as Senior Research Fellow in 2010 and promoted to Assistant Professor in 2023.

I received a 2019 British Association for Psychopharmacology (BAP) in non-clinical psychopharmacology, and from 2019-2023 I was member of the British Journal of Pharmacology Editorial Board . I am BAP until summer 2025.

Expertise Summary

I have expertise in a broad range of behavioural techniques (using the latest software for computerised tracking, visual touchscreen tasks and recording of ultrasonic vocalisations), complimentary molecular approaches and access to state of the art magnetic resonance spectroscopy (MRS).

Teaching Summary

I teach on year 2-4 of the Neuroscience degree, on topics related to my research. I am also a personal tutor and I supervise final year research projects.

I have achieved Fellowship of the Higher Education Academy (FHEA) in recognition of my commitment to professionalism in learning and teaching in higher education.

Research Summary

My research uses neurodevelopmental models to understand how stress and adversity impact on brain function and contribute to cognitive and social dysfunction. The same models are extremely useful for… read more

Selected Publications

  • GOH J-Y, O'SULLIVAN SE, SHORTALL SE, ZORDAN N, PICCININI AM, POTTER HG, FONE KCF and KING MV, 2020. Brain, Behavior, and Immunity. 89, 100-117
  • SHORTALL SE, BROWN AM, NEWTON-MANN E, DAWE-LANE E, EVANS C, FOWLER M and KING MV, 2020. Molecular Neurobiology. 57, 3439鈥�3457
  • KOHLI S, KING MV, WILLIAMS S, EDWARDS A, BALLARD TM, STEWARD LJ, ALBERATI D and FONE KCF, 2019. Neuropsychopharmacology. 44(2), 295-305
  • SHORTALL SE, NEGM OH, FOWLER M, FAIRCLOUGH LC, TIGHE PJ, WIGMORE PM and KING MV, 2018. Molecular Neurobiology. 55(9), 7413-7430

Current Research

My research uses neurodevelopmental models to understand how stress and adversity impact on brain function and contribute to cognitive and social dysfunction. The same models are extremely useful for evaluating novel treatments for conditions like schizophrenia, autism and depression. Our group has a track record of successful collaboration on EU and industry-funded projects evaluating novel therapeutics. Current group members are working on a variety of exciting projects; Developing in vitro models for stress-related mental illnesses, Investigating biased signalling at G protein-coupled receptors, Evaluating nanoparticle approaches to enhance nose-brain delivery of therapeutic peptides, and Developing bespoke nanocarriers for controlled encapsulation and release of therapeutic peptides.

I am always keen to establish new links with academic and industrial researchers - if you are interested please contact me via email.

Future Research

I am happy to consider new self-funded postgraduate students for the 2026-27 academic year. Potential projects involve:

  1. Assessing changes to the gut microbiota in models for stress-related mental illnesses, and potential normalization by probiotics
  2. Characterising brain regional transcriptomic changes, and their pharmacological reversal, in models for stress-related mental illnesses
  3. Validating behavioural tests for social learning/empathy
  4. Evaluating nanoparticle approaches to enhance nose-brain delivery of prosocial peptides

Information about applying can be found here.

  • ESUAIKOH V, IBEGBULAM S, COOK A, MCFARLAND B, NUNNINGTON N, PERERA A, FENG J, CALE JA and KING MV, 2026. Frontiers in Cellular Neuroscience. 20, 1784522
  • WONG, SARA, BROWN, ALEXANDER D., ABRAHAMS, ABIGAIL B., NURZAK, AN NISAA, ELTAHER, HODA M., SYKES, DAVID A., VEPRINTSEV, DMITRY B., FONE, KEVIN C. F., DIXON, JAMES E. and KING, MADELEINE V., 2024. Pharmaceutics. 16(10),
  • CALE JA, CHAUHAN EJ, CLEAVER JJ, FUSCIARDI AR, MCCANN S, WATERS HC, 沤AVBI J and KING MV, 2024. Molecular Neurobiology. 61, 6968鈥�6983
  • GOH JY, RUEDA P, TAYLOR J, RATHBONE A, SCOTT D, LANGMEAD CJ, FONE KCF, STEWART GD and KING MV, 2024. Neurobiology of Stress. 33, 100679
  • SHORTALL SE, BROWN AM, NEWTON-MANN E, DAWE-LANE E, EVANS C, FOWLER M and KING MV, 2020. Molecular Neurobiology. 57, 3439鈥�3457
  • GOH J-Y, O'SULLIVAN SE, SHORTALL SE, ZORDAN N, PICCININI AM, POTTER HG, FONE KCF and KING MV, 2020. Brain, Behavior, and Immunity. 89, 100-117
  • KOHLI S, KING MV, WILLIAMS S, EDWARDS A, BALLARD TM, STEWARD LJ, ALBERATI D and FONE KCF, 2019. Neuropsychopharmacology. 44(2), 295-305
  • DUNPHY DOHERTY F, O鈥橫AHONY SM, PETERSON VL, O鈥橲ULLIVAN O, CRISPIE F, COTTER PD, WIGMORE P, KING MV, CRYAN JF and FONE KCF, 2018. Brain, Behavior and Immunity. 68, 261-273
  • SHORTALL SE, NEGM OH, FOWLER M, FAIRCLOUGH LC, TIGHE PJ, WIGMORE PM and KING MV, 2018. Molecular Neurobiology. 55(9), 7413-7430
  • SHORTALL SE, GREEN AR, FONE KC and KING MV, 2016. Journal of psychopharmacology (Oxford, England). 30(7), 698-706
  • WATSON DJ, KING MV, GYERTY脕N I, KISS B, ADHAM N and FONE KC, 2016. European Neuropsychopharmacology. 26(2), 208-24
  • SHORTALL SE, SPICER CH, EBLING FJ, GREEN AR, FONE KC and KING MV, 2016. Addiction Biology. 21(6), 1127-1139
  • KING, M.V., KURIAN, N., QIN, S., PAPADOPOULOU, N., WESTERINK, B.H.C., CREMERS, T.I., EPPING-JORDAN, M.P., LE POUL, E., RAY, D.E., FONE, K.C.F., KENDALL, D.A., MARSDEN, C.A. and SHARP, T.V., 2014. Neuropsychopharmacology. 39(2), 464-476
  • GREEN AR, KING MV, SHORTALL SE and FONE KCF, 2014. British Journal of Pharmacology. 171(9), 2251-2268
  • JONES S, FILECCIA EL, MURPHY M, FOWLER MJ, KING MV, SHORTALL SE, WIGMORE PM, GREEN AR, FONE KCF and EBLING FJP, 2014. Neuroscience letters. 559, 34-8
  • WRIGHT TM, KING MV, DAVEY WG, LANGLEY-EVANS SC and VOIGT JW, 2014. The British journal of nutrition. 112, 1933-7
  • SHORTALL, S.E., GREEN, A.R., SWIFT, K.M., FONE, K.C.F. and KING, M.V., 2013. British Journal of Pharmacology. 168(4), 966-977
  • SHORTALL, S.E., MACEROLA, A.E., SWABY, R.T.R., JAYSON, R., KORSAH, C., PILLIDGE, K.E., WIGMORE, P.M., EBLING, F.J.P., GREEN, A.R., FONE, K.C.F. and KING, M.V., 2013. European Neuropsychopharmacology. 23(9), 1085-1095
  • GREEN AR, KING MV, SHORTALL SE and FONE KCF, 2012. British Journal of Pharmacology. 166(5), 1523-36
  • GREEN, A. R., KING, M. V., SHORTALL, S. E. and FONE, K. C. F., 2012. British Journal Of Pharmacology. 166(5), 1521-1522
  • MARSDEN, C.A., KING, M.V. and FONE, K.C.F., 2011. Neuropharmacology. 61(3), 400-407
  • KING, M.V., SPICER, C.H., SLEIGHT, A.J., MARSDEN, C.A. and FONE, K.C.F., 2009. Psychopharmacology. 202(1-3), 111-123
  • KING MV, SEEMAN P, MARSDEN CA and FONE KC, 2009. Synapse (New York, N.Y.). 63(6), 476-83
  • KING M.V, MARSDEN C.A and FONE K.C., 2008. Trends Pharmacol Sci. 29(9), 482-492
  • KING M.V, SLEIGHT A.J, WOOLLEY M.L, TOPHAM I.A, MARSDEN C.A and FONE K.C., 2004. Neuropharmacology. 47(2), 195-204

School of Life Sciences

糖心原创
Medical School
Queen's Medical Centre
Nottingham NG7 2UH

e: life-sciences@nottingham.ac.uk
t: +44 (0)115 823 0141
f: +44 (0)115 823 0142